Cargando…
Targeting MDM4 Splicing in Cancers
MDM4, an essential negative regulator of the P53 tumor suppressor, is frequently overexpressed in cancer cells that harbor a wild-type P53. By a mechanism based on alternative splicing, the MDM4 gene generates two mutually exclusive isoforms: MDM4-FL, which encodes the full-length MDM4 protein, and...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333071/ https://www.ncbi.nlm.nih.gov/pubmed/28230750 http://dx.doi.org/10.3390/genes8020082 |
_version_ | 1782511655511392256 |
---|---|
author | Bardot, Boris Toledo, Franck |
author_facet | Bardot, Boris Toledo, Franck |
author_sort | Bardot, Boris |
collection | PubMed |
description | MDM4, an essential negative regulator of the P53 tumor suppressor, is frequently overexpressed in cancer cells that harbor a wild-type P53. By a mechanism based on alternative splicing, the MDM4 gene generates two mutually exclusive isoforms: MDM4-FL, which encodes the full-length MDM4 protein, and a shorter splice variant called MDM4-S. Previous results suggested that the MDM4-S isoform could be an important driver of tumor development. In this short review, we discuss a recent set of data indicating that MDM4-S is more likely a passenger isoform during tumorigenesis and that targeting MDM4 splicing to prevent MDM4-FL protein expression appears as a promising strategy to reactivate p53 in cancer cells. The benefits and risks associated with this strategy are also discussed. |
format | Online Article Text |
id | pubmed-5333071 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-53330712017-03-13 Targeting MDM4 Splicing in Cancers Bardot, Boris Toledo, Franck Genes (Basel) Review MDM4, an essential negative regulator of the P53 tumor suppressor, is frequently overexpressed in cancer cells that harbor a wild-type P53. By a mechanism based on alternative splicing, the MDM4 gene generates two mutually exclusive isoforms: MDM4-FL, which encodes the full-length MDM4 protein, and a shorter splice variant called MDM4-S. Previous results suggested that the MDM4-S isoform could be an important driver of tumor development. In this short review, we discuss a recent set of data indicating that MDM4-S is more likely a passenger isoform during tumorigenesis and that targeting MDM4 splicing to prevent MDM4-FL protein expression appears as a promising strategy to reactivate p53 in cancer cells. The benefits and risks associated with this strategy are also discussed. MDPI 2017-02-20 /pmc/articles/PMC5333071/ /pubmed/28230750 http://dx.doi.org/10.3390/genes8020082 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bardot, Boris Toledo, Franck Targeting MDM4 Splicing in Cancers |
title | Targeting MDM4 Splicing in Cancers |
title_full | Targeting MDM4 Splicing in Cancers |
title_fullStr | Targeting MDM4 Splicing in Cancers |
title_full_unstemmed | Targeting MDM4 Splicing in Cancers |
title_short | Targeting MDM4 Splicing in Cancers |
title_sort | targeting mdm4 splicing in cancers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333071/ https://www.ncbi.nlm.nih.gov/pubmed/28230750 http://dx.doi.org/10.3390/genes8020082 |
work_keys_str_mv | AT bardotboris targetingmdm4splicingincancers AT toledofranck targetingmdm4splicingincancers |